Generic placeholder image

Inflammation & Allergy - Drug Targets (Discontinued)


ISSN (Print): 1871-5281
ISSN (Online): 2212-4055

Lactobacillus Rhamnosus Cell Lysate in the Management of Resistant Childhood Atopic Eczema

Author(s): Ba X. Hoang, Graeme Shaw, Phuong Pham and Stephen A. Levine

Volume 9, Issue 3, 2010

Page: [192 - 196] Pages: 5

DOI: 10.2174/187152810792231896

Price: $65


The number of children suffering from atopic eczema has increased over the past 30 years especially in children between the ages of 2 and 5 years. There is a significant group of eczematous children that are resistant to standard therapy. Babies and children with eczema suffer pain, irritation and disfigurement from the dermatitis. In this study, we have followed 14 cases of pediatric patients (ages of 8 months to 64 months) with a history of resistant eczema for a period of at least six months. All of these children received 300 mg to 500 mg standardized Lactobacillus rhamnosus cell lysate daily as an immunobiotic supplement. The results of this open label non-randomized clinical observation showed a substantial improvement in quality of life, skin symptoms and day- and nighttime irritation scores in children with the supplementation of Lactobacillus rhamnosus lysate. There were no intolerance or adverse reactions observed in these children. Lactobacillus rhamnosus cell lysate may thus be used as a safe and effective immunobiotic for the treatment and prevention of childhood eczema and possible other types of atopy (allergic diseases).

Keywords: Atopic eczema, dermatitis, lactobacillus lysate, probiotic, inflammation

Rights & Permissions Print Export Cite as
┬ę 2023 Bentham Science Publishers | Privacy Policy